Special Issue "Lymphoma"

Quicklinks

A special issue of Cancers (ISSN 2072-6694).

Deadline for manuscript submissions: 31 October 2014

Special Issue Editors

Guest Editor
Prof. Dr. Georg Lenz
Department of Hematology, Oncology and Tumor Immunology, Charité -Universitätsmedizin Berlin, 13353 Berlin, Germany
Website: http://mkfz.charite.de/forschung/forschungsgruppen/ag_lenz/
E-Mail: georg.lenz@charite.de
Interests: lymphomas, molecular pathogenesis of aggressive lymphomas, NF-kB, gene expression profiling

Guest Editor
Prof. Dr. Martin Dreyling
Department of Medicine III, University Hospital Grosshadern/LMU, CCG Leukemia, Marchioninistr. 15, 81377 Munich, Germany
Website: http://www.klinikum.uni-muenchen.de/Medizinische-Klinik-und-Poliklinik-III/de/team/oberaerzte/dreyling_m/index.html
E-Mail: Martin.Dreyling@med.uni-muenchen.de
Interests: lymphomas, therapy and molecular pathogenesis

Special Issue Information

Dear Colleagues

Malignant lymphomas represent transformations within the lymphoid system. Various subtypes with divergent biology, morphology, clinical presentation, and prognosis can be distinguished. Despite substantial recent progress in the understanding of the molecular pathogenesis of these malignancies, as well as their treatment, still a substantial fraction of affected patients cannot be cured with current therapy. Especially, patients affected by lymphomas that are refractory to conventional immunochemotherapy represent a major clinical problem. Thus, a significantly better understanding of the biology of lymphomagenesis is urgently warranted. This will enable us to incorporate novel molecular targeted therapies into the treatment of affected patients and improve their outcome. This special issue focuses on novel advances in the understanding of the molecular mechanisms leading to lymphoma development, as well as on the development of novel therapeutic regimens to improve prognosis of affected patients.

Prof. Dr. Georg Lenz
Prof. Dr. Martin Dreyling
Guest Editors

Submission

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. Papers will be published continuously (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are refereed through a peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed Open Access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 800 CHF (Swiss Francs).

Keywords

  • lymphoma
  • chemotherapy
  • antibodies
  • small molecules
  • biology
  • molecular pathogenesis

Published Papers

No papers have been published in this special issue yet.

Last update: 8 April 2014

Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert